English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 911735      Online Users : 944
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/4974


    Title: Histamine-2-receptor antagonist are an alternative to proton pump inhibitor in patients receiving clopidogrel
    Authors: Wu, CY;Chan, FK;Wu, MS;Kuo, KN;Wang, CB;Tsao, CR;Lin, JT
    Contributors: Division of Health Policy Research and Development
    Abstract: BACKGROUND AND AIMS:: Previous observational studies reported that concomitant use of clopidogrel and proton pump inhibitors (PPIs) in patients with prior acute coronary syndrome (ACS) was associated with adverse cardiovascular outcomes. We investigated whether H(2)-receptor antagonist (H(2)RA) is an alternative to PPI in patients with ACS. METHODS:: We conducted a population-based retrospective cohort study of 6,552 patients in Taiwan discharged for ACS between 2002 and 2005. Patients were divided into five cohorts: clopidogrel plus H(2)RA (252), clopidogrel plus PPI (311), clopidogrel alone (5,551), H(2)RA alone (235), and PPI alone (203). The primary outcome was rehospitalization for ACS or all-cause mortality within 3 month of rehospitalization. RESULTS:: The one-year cumulative incidence of the primary outcome was 26.8% (95% CI: 21.5-33.0%) in the clopidogrel plus H(2)RA cohort and 33.2% (95% CI: 27.8-39.4%) in the clopidogrel plus PPI cohort, compared to 11.6% (95% CI: 10.8-12.5%) in the clopidogrel alone cohort (P<0.0001). There was no significant difference between the PPI alone cohort (11.0%, 95% CI: 7.1-16.8%), the H(2)RA alone cohort (11.8%, 95% CI: 8.2-16.8%), and the clopidogrel alone cohort in terms of the primary outcome. The number needed to harm was 7 with concomitant H(2)RA and 5 with concomitant PPI. On multivariate analysis, concomitant H(2)RA and PPI were independent risk factors predicting adverse outcomes (adjusted hazard ratios, 2.48 and 3.20, respectively, P<0.0001). CONCLUSIONS:: Concomitant use of clopidogrel and H(2)RA or PPI after hospital discharge for ACS is associated with increased risk of adverse outcomes.
    Date: 2010-10
    Relation: Gastroenterology. 2010 Oct;139(4):1165-1171.e4.
    Link to: http://dx.doi.org/10.1053/j.gastro.2010.06.067
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0016-5085&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000282372700026
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77957338399
    Appears in Collections:[郭耿南(2003-2010)] 期刊論文

    Files in This Item:

    File Description SizeFormat
    PB2010081007.pdf429KbAdobe PDF393View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback